Latest news with #UnitedStatesPatentandTrademarkOffice
Time Business News
5 days ago
- Business
- Time Business News
Do I Need to Trademark in the U.S. if I Already Registered in the UK?
For UK businesses expanding into the United States, a common question arises: if you already hold a registered trademark in the UK, is it necessary to register the same trademark in the U.S.? The short answer is yes. A UK trademark does not offer protection in the U.S. Without U.S. registration, your brand may be unprotected in one of the world's largest markets. Trademarks are inherently territorial. A UK registration only protects your brand within the UK. If you're entering the U.S. market, you'll need to protect your intellectual property there too. Without a U.S. registration, if a local competitor uses or registers your mark, you may have limited options to stop them—even if you've used the mark in the UK for years. That's why many companies consult a commercial contract lawyer to align IP rights with contractual protections and mitigate the risks of brand dilution or market exclusion. In addition, registering your trademark in the U.S. demonstrates your commitment to operating legitimately in the market, which can strengthen relationships with distributors, partners, and investors. Operating without a registered U.S. trademark brings multiple risks: Loss of brand exclusivity Legal action from a U.S. company holding the mark Customs block on imported goods bearing the unregistered mark Inability to secure a .com domain or U.S.-specific social media handles Barriers to launching U.S. marketing campaigns or influencer partnerships These issues can delay your market entry and increase legal exposure, particularly in highly competitive sectors. The United States follows a first-to-use system, but federal protection under the United States Patent and Trademark Office (USPTO) provides stronger legal benefits. Key benefits of U.S. trademark registration: Nationwide legal protection and presumptive ownership Public listing of your brand in the USPTO database Right to use the ® symbol in the U.S. Ability to block infringing imports via U.S. Customs Enhanced leverage in litigation and commercial negotiations If you haven't launched in the U.S. yet, you can file an Intent to Use (ITU) application, allowing you to secure rights before sales begin. Many companies also use escrow structures to hold rights or payments pending registration. You should apply for a U.S. trademark as soon as: You plan to sell to U.S. customers (online or offline) You're signing U.S. distribution or licensing agreements You want to secure your brand for long-term expansion You're rebranding or designing packaging for global distribution Engaging a firm with escrow services uk capability can also support any associated licensing or commercial IP deals requiring secure payment arrangements. This is often a core feature of IP transfers or brand partnerships where risk is shared between parties. Absolutely. There are experienced us lawyer that can manage the entire process—from trademark clearance searches to filing, prosecution, and enforcement. This means you don't have to coordinate between jurisdictions or worry about miscommunication between two different legal teams. Dual-qualified lawyers can handle both your UK and U.S. trademark portfolios, alongside related commercial matters, such as IP clauses in international agreements. Having a local point of contact in London makes legal strategy more accessible and efficient for UK businesses, especially those with limited in-house counsel resources. At Abrams Law, we are dual-qualified UK solicitors and U.S. Attorneys. We offer: U.S. trademark search and filing via USPTO Monitoring and enforcement of U.S. trademark rights Guidance on protecting IP in commercial contract agreements Assistance with escrow services for brand licensing or sale transactions Local expertise on cross-border compliance, marketing risk, and legal remedies We act as a bridge between jurisdictions, ensuring your brand is protected in both the UK and U.S. markets. Expanding into the U.S. without securing your trademark is a high-risk move. Don't leave your intellectual property exposed. Speak to a commercial contract lawyer with U.S. experience today. 📧 Email: info@ 📞 Phone: +44 208 004 7016 TIME BUSINESS NEWS
Miami Herald
02-06-2025
- Automotive
- Miami Herald
GM Files Trademark for 'Panther' Name, Sparking Speculation on Camaro Successor
General Motors has filed a trademark for the Panther name with the United States Patent and Trademark Office, and it has again sent the rumor mills into overdrive about the revival of the Camaro sports car. Panther was the codename for the original Camaro during development, and a panther resurfaced in the Camaro Collector's Edition's logo. We don't think a Camaro revival is in the cards, so what is Panther all about then? GM has said there's simply no business case for a new Camaro, but Panther could still bring some excitement in the form of a smaller and more affordable sports car in the mold of the Toyota GR86. This would be much cheaper to develop than a real V8 pony car, but profit margins will also be slimmer, which is why Toyota shares the development costs of its sports cars with other automakers - Subaru in the case of the GR86 and BMW in the case of the GR Supra. It's not easy making a business case for sports cars these days. The Camaro went out of production in December 2023, and in its last model year on the market, Chevrolet sold only 6,000 of them, down from a high point of 70,000 in 2016. In fact, so slow was the stock to deplete that some dealers still had new Camaros left on the lot in February 2025. A trademark application doesn't mean much either, as GM has also filed a trademark for Pontiac recently, and that doesn't mean the brand is being revived. A compact sportster on a shared platform could happen, but we don't know how GM will make it work in the current climate, and the way the market is leaning toward EVs. The next Camaro was envisioned as an electric sedan back in 2021, and this could still be a possibility, though we shouldn't be surprised if it morphs into an SUV, the way Ford has done with its Mustang Mach-E and the new Capri. An electric crossover called the Panther would certainly be less controversial than the hallowed Camaro name on an SUV. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Yahoo
28-05-2025
- Business
- Yahoo
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two design patents and one utility patent covering the Company's novel fenestrated human placental allograft designs and compositions manufactured using the BioREtain® process. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem's Design Patent Application No. 29/860,417 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT and for Design Patent Application No. 29/860,420 for FENESTRATED HUMAN PLACENTAL ALLOGRAFT. These patents pertain to novel and inventive fenestrated human placental allograft designs manufactured using the BioREtain process. The unique design allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area, thereby facilitating drainage and providing an environment that is more conducive to healing. Additionally, the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for BioStem's Patent Application No. 18/926,867 for STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON. This patent pertains to novel and inventive fenestrated human placental allograft compositions manufactured using the BioREtain process with a unique fenestration that allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area. The method of preparation preserves the structural and molecular integrity of the amnion and chorion tissues, thereby facilitating and enhancing wound treatment compared to conventional human placental allografts, particularly in the treatment of diabetic foot ulcers, dental wounds, and other topical Matuszewski, Chief Executive Officer of BioStem Technologies, commented: 'BioStem is actively expanding its patent portfolio to accelerate product innovation and drive the development of new products that elevate the standard of wound care. These newly granted patents play a pivotal role in the advancement of our next-generation placental allograft technologies and underscore the proprietary nature of our BioREtain process - designed to preserve the structural and molecular integrity of the placental tissue. By optimizing the retention and preservation of the amnion, intermediate, and chorion layers, we are able to offer clinicians solutions that support better outcomes and improve patient care. This continued innovation further solidifies BioStem's leadership in advanced wound care.' Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Forward-Looking Statements:Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Contact BioStem Technologies, Inc.:Phone: 954-380-8342Website: info@ @BSEM_TechFacebook: BioStemTechnologies Investor Relations:Adam HoldsworthE-Mail: adam@ 917-497-9287
Business Wire
21-05-2025
- Business
- Business Wire
Sutherland Awarded U.S. Patent for Sentinel AI ®, Securing Remote Work with AI
ROCHESTER, N.Y.--(BUSINESS WIRE)-- Sutherland, a global leader in business and digital transformation, has been granted a patent by the United States Patent and Trademark Office (USPTO) for Sutherland Sentinel AI ®. This innovative AI-driven data protection platform redefines compliance, data security, and risk management for today's remote and hybrid work environments. The platform powers secure remote operations and real-time data redaction for leading finance, telecom, and healthcare companies, safeguarding sensitive information for millions of users and billions of transactions worldwide. Share Sentinel AI delivers real-time security enforcement, enhancing existing solutions to protect sensitive data across distributed workplaces while maintaining productivity. The platform powers secure remote operations and real-time data redaction for leading finance, telecom, and healthcare companies, safeguarding sensitive information for millions of users and billions of transactions worldwide. The patented Sentinel AI ® Shield uses AI-powered dynamic data masking to secure sensitive information within applications, eliminating the need for costly rewrites or backend infrastructure changes. Machine learning algorithms automatically tailor masking rules to align with each organization's privacy, security, and compliance needs. Paired with Sentinel AI ® Vision, which uses facial recognition and environmental cues to monitor real-time compliance, the platform helps establish a strong zero-trust framework for remote operations. 'Enterprises shouldn't have to choose between scaling fast and staying secure, said Doug Gilbert, Chief Information Officer and Chief Digital Officer at Sutherland. "With Sentinel AI, we are changing the game — making compliance and data protection seamless, intelligent, and built for a digital-first world.' Real-World Results with Sentinel AI ® Across industries, Sentinel AI is already making a measurable impact. A global financial services provider used Sentinel AI ® Shield to secure over 2 million client interactions and accelerate secure deployment across 40+ enterprise applications, reducing audit deployment times and freeing up 80% of SME bandwidth. A leading U.S. telecom company deployed the platform to strengthen FCC compliance. It implemented field-level data masking without code changes and enabled same-day security updates through centralized management. And in the healthcare sector, Sentinel AI ® Vision helped a national provider exceed audit expectations while cutting supervisory monitoring time by 40% and achieving a 50x reduction in audit manpower through automated reporting and real-time risk detection. For industries where data privacy is non-negotiable, Sentinel AI delivers proven impact: Robust compliance – Eliminates regulatory penalties and minimizes remote work risks with its compliance-first framework, customizable across industries and regulatory requirements. Productivity at scale – Minimizes audit workloads, freeing teams to focus on strategic tasks. Proven cost savings – Reduces supervisor monitoring time by up to 90%, translating into millions in savings annually. Always-on security – Continuous monitoring that uses AI-led redaction to ensure compliance is never an afterthought. Sutherland Sentinel AI ® is one of the latest additions to Sutherland's growing portfolio of patented innovations. With over 200 unique inventions spanning AI, automation, and other critical technologies, Sutherland continues to strengthen its technology and intellectual property leadership in digital transformation. About Sutherland Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics. For Enterprises, these are key factors of success. For us, they're our core expertise. We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering - the foundation that powers rapid innovation and scalable business transformation. We've created over 200 unique inventions under several patents across AI and other emerging technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless "as-a-service" model. For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don't just enable change - we engineer digital outcomes. Sutherland digital outcomes.
Hindustan Times
19-05-2025
- Business
- Hindustan Times
People in US, UK enter race to claim ‘Operation Sindoor' trademark: Report
Petitioners from the United States and the United Kingdom have also entered the race to claim the trademark for the phrase 'Operation Sindoor," for a range of sectors including entertainment, media and broadcasting, reported the Bar and Bench. As of mid-May 2025, at least 14 applications have been filed in India requesting to claim the trademark for various segments across entertainment-related services like audio and video content. Reliance Industries Ltd was among the early ones to file the applications, however, later it withdrew stating that it was filed 'inadvertently' by a junior employee 'without authorisation'. In the US, Rohith Baharani, a New York-based individual, submitted a trademark application on May 9 under International Class 041, which is designated for a 'trademarked entertainment title for licensing,' according to Bar and Bench. The filing was made on an 'intent to use' (ITU) basis—indicating that while the mark is not yet in commercial use, there are plans to utilize it in the future. The application is currently under review by the United States Patent and Trademark Office (USPTO) within U.S. Classes 100, 101, and 107, which cover certification and service marks, the Bar and Bench report said. Meanwhile, in the UK, Vikas Mahajan, a resident of Devon, England, filed for the same mark on May 8, 2025, with the UK Intellectual Property Office (UKIPO). His application spans Classes 35, 38, and 41, covering advertising, telecommunications, and education-related services. If either application is approved, the registrants will gain exclusive rights within their respective countries for the registered classes. These rights include the ability to enforce against unauthorised use, license the trademark commercially, and initiate infringement actions. However, trademark protection is territorial—meaning ownership in the US or UK doesn't automatically confer rights in India unless a separate filing or the mark is protected under an international registration through the Madrid Protocol. "Operation Sindoor" is a military codename given to a recent cross-border strike by the Indian armed forces launched on May 7 in the wake of a terror attack in J&K's Pahalgam. The name was chosen with intention — and profound emotion. The terror attack in Pahalgam on April 22, which took the lives of 26 people, most of them male tourists, left devastation in its wake. Grieving wives, still adorned with sindoor (the traditional mark of marriage) were seen mourning, their lives forever changed in a moment. That haunting image resonated deeply across the nation. The operation was named 'Sindoor' as a tribute to those women. Defence minister Rajnath Singh had earlier said that the name 'Operation Sindoor' is the brainchild of Prime Minister Narendra Modi. In India, the government does not automatically own the intellectual property rights to military codenames. However, under the Trade Marks Act, 1999, the body can reject the applications that are offensive, misleading or against the public interest.
